TB
This clinical-stage biotechnology company utilizes computational data science and proprietary biomarkers to match cancer-specific antigens with patients' immune recognition mechanisms. This approach enables the development of personalized vaccines and diagnostic tests, enhancing treatment efficacy for cancer patients.
Updated 2 months ago
Funding
$51.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LVTF
Funding rounds are not available yet.
Founders
Product
Features
- This clinical-stage biotechnology company utilizes computational data science and proprietary biomarkers to match cancer-specific antigens with patients' immune recognition mechanisms. This approach enables the development of personalized vaccines and diagnostic tests, enhancing treatment efficacy for cancer patients.